Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 3/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10910262 | 0.82 | CYP3A4 (0.45) | SLC6A3ALDH1A1HTTSMN1; SMN2PTGS1 | |
| SCHEMBL11070316 | 0.80 | SLC6A3 (0.47) | SLC6A3SLC6A4SLC6A2ALDH1A1LMNA | |
| SCHEMBL8897255 | 0.79 | ALDH1A1 (0.45) | SLC6A3SLC6A4SLC6A2ALDH1A1LMNA | |
| SCHEMBL20459542 | 0.79 | SLC6A3 (0.42) | SLC6A3SLC6A4SLC6A2ALDH1A1LMNA | |
| SCHEMBL11567407 | 0.79 | SLC6A3 (0.46) | SLC6A3SLC6A4SLC6A2ALDH1A1LMNA | |
| SCHEMBL15484869 | 0.78 | AKR1C3 (0.42) | IDO1 | |
| SCHEMBL6565095 | 0.77 | ESR1 (0.43) | ALDH1A1 | |
| SCHEMBL10910506 | 0.76 | TSHR (0.50) | ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL909757 | 0.76 | ADRB2 (0.50) | SLC6A3SLC6A2ALDH1A1LMNAHTT | |
| SCHEMBL5789630 | 0.75 | SLC6A3 (0.50) | SLC6A3SLC6A4SLC6A2AHRIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023135233-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2023-07-20 | — | — | WO | disclosed |
| EP-4212531-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery (FR) | 2023-07-19 | — | — | EP | disclosed |
| US-7855292-B2 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-21 | — | — | US | disclosed |
| US-20100292240-A1 | SULFONAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| US-20080132511-A1 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | JANSSEN PHARMACEUTICA NV (BE) | 2008-06-05 | — | — | US | disclosed |
| US-7297816-B2 | Sulfonamide compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-20 | — | — | US | disclosed |
| CN-101061116-A | Sulfonamide compounds | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-24 | — | — | CN | disclosed |
| EP-1797083-A1 | SULFONAMIDE COMPOUNDS | Janssen Pharmaceutica, N.V. (BE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006036670-A1 | SULFONAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069286-A1 | Sulfonamide compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132511-A1 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | CCKAR, CCKBR, GRPR | SLC6A3 260/4885SLC6A4 610/4885SLC6A2 443/4885 |
| US-20100292240-A1 | SULFONAMIDE COMPOUNDS | CCKAR, CCKBR, TAS1R2 | SLC6A3 2135/4885SLC6A4 1827/4885SLC6A2 1859/4885 |
| US-20060069286-A1 | Sulfonamide compounds | CCKAR, CCKBR, TAS1R2 | SLC6A3 2135/4885SLC6A4 1827/4885SLC6A2 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.